Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer
Open Access
Abstract
Background: Urothelial bladder cancer (UBC) is a molecularly heterogeneous disease, and most sequencing studies have relied on bladder-specific or solid tumor-restricted panels. Whether broader pan-cancer assays provide additional clinically relevant information remains unclear. Methods: We performed targeted next-generation sequencing using an extended gene panel on tumor samples from 100 patients with UBC treated at a tertiary center. Somatic single-nucleotide variants, small insertions/deletions, copy-number alterations, and gene co-occurrence patterns were analyzed and correlated with clinicopathological features, disease-free survival (DFS), and overall survival (OS). Results: Recurrent alterations were identified in FGFR3 (≈50%), TP53 (≈35%), STAG2 (≈25%), and PIK3CA (≈20%), consistent with established molecular pathways in UBC. Less frequent but potentially actionable alterations, including mutations in BRCA1 and ALK, were also detected, reflecting the extended coverage of the panel. TP53 mutations were independently associated with worse OS, whereas STAG2 alterations were associated with improved OS, particularly in tumors without concurrent TP53 mutations. FGFR3 mutations showed a favorable but non-independent trend. No gene retained independent prognostic significance for DFS. Co-occurrence analysis revealed an FGFR3/PIK3CA-associated pathway and relative mutual exclusivity between FGFR3 and TP53. Copy-number alterations were modest overall. Comparison with TCGA data demonstrated a higher frequency of FGFR3 alterations in our cohort, likely reflecting the larger proportion of non–muscle-invasive tumors. Conclusions: Pan-cancer targeted sequencing provided a comprehensive genomic landscape of UBC, capturing canonical drivers and additional alterations that may be overlooked by bladder-restricted assays. The identification of TP53 and STAG2 as prognostic markers highlights the potential value of broader genomic profiling for biologically informed risk stratification in urothelial bladder cancer.Keywords
This publication has 57 references indexed in Scilit:
- Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial CancerEuropean Urology Open Science, 2025
- Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder CancerCurrent Urology Reports, 2024
- Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategiesCancer Treatment Reviews, 2024
- TP53 mutations in urothelial carcinoma: not all one and the same†The Journal of Pathology, 2024
- Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat PanelClinical Genitourinary Cancer, 2024
- Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder CancerTargeted Oncology, 2024
- STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical OutcomesEuropean Urology Open Science, 2022
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)European Urology, 2022
- Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samplesVirchows Archiv, 2018
- Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancerTumor Biology, 2016